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FERTILITY PRESERVATION FOR MEDICAL
REASONS AND REPRODUCTIVE
JUSTICE
Seema Mohapatra1
ABSTRACT
This Article addresses the issues related to fertility preservation in the
emerging area of fertility preservation for medical reasons using a repro-
ductive justice framework.  Fertility preservation for medical reasons re-
fers to the process of preserving the fertility of women (and men) who
need to undergo treatments that may cause reduced fertility or sterility.
This process typically involves counseling a patient about the potential
fertility consequences of their cancer treatment, and then if a patient so
chooses (and can afford it), freezing the eggs (or sperm) to potentially use
later via in vitro fertilization or using a gestational surrogate.  As cancer
survival rates improve, the ability to bear children after therapy is in-
creasingly a concern for many patients.  Some patients may choose their
cancer therapy based on the risk of fertility loss rather than on its effec-
tiveness to cure the cancer.  Unfortunately, a patient’s race and insurance
status often determines if and when they are told about the fertility conse-
quences of their treatment.  Those without insurance are often already
financially challenged after a cancer diagnosis, so physicians may not in-
form them about fertility preservation due to the high costs.
No states currently have laws requiring insurance coverage for fertil-
ity preservation for medical reasons.  Therefore, even if a patient has in-
surance, fertility preservation may not be covered.  As a practical matter,
when insurance companies deny fertility preservation coverage, there is
often a short time frame between diagnosis and treatment that does not
allow time to seek appeal.  Those able to pay for fertility preservation for
medical reasons are likely white, educated, middle- and upper-class wo-
men, similar to the population able to access general assisted reproduc-
tive technology (ART).
More recently, however, fertility preservation for medical reasons cov-
erage has been getting more support.  In June 2013, the American Medical
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Association (AMA) endorsed a policy that supports payment for fertility
preservation and lobbies for appropriate federal legislation requiring that
insurers pay for fertility preservation for medical reasons.  This new pol-
icy treats the risk of infertility as a medical condition, not a choice, when
the disease or treatment affects biological motherhood.  Additionally,
California is currently considering CA bill AB 912, which would require
insurance companies to provide coverage for medically necessary ex-
penses for standard fertility preservation services when a medical treat-
ment may cause infertility.  If this bill is approved, it may improve the
quality of life for cancer survivors who have health insurance.  Although
this is encouraging, this also has the real potential to exacerbate the di-
vide between the patient “haves” and “have-nots.”
Cancer has a disproportionately severe impact on minorities.  The
Centers for Disease Control and Prevention report that cancer death rates
for women are highest among African Americans, followed by Cauca-
sians, Hispanics, and Asian/Pacific Islanders.  Cancer has been the lead-
ing cause of death for female Asian Americans since 1980.  Some of the
disproportionate impact has been attributed to delayed diagnosis as well
as poor patient care.  Poor people who lack health insurance or have inad-
equate access to quality cancer treatment also experience higher cancer
incidence, higher mortality rates, and lower survival rates than their more
well off counterparts.
Because fertility preservation for medical reasons is not currently cov-
ered by either private or public insurance, only those who can pay for it
on their own can use it.  Some scholars have argued that it should be
covered by insurance.  Others contend that adding fertility preservation
for medical reasons to insurance coverage, without expanding health care
coverage to those without insurance, may reinforce socioeconomic ine-
quality.  Additionally, an important study suggests that oncologists are
less likely to discuss fertility preservation for medical reasons with Afri-
can American women, regardless of income, than white women.  This Ar-
ticle discusses this evidence and whether fertility preservation for
medical reasons can be structured in a manner to promote reproductive
justice.  I also review fertility preservation for medical reasons with a re-
productive health, reproductive rights, and reproductive fairness frame-
work to identify normative standards for use and informed consent in
fertility preservation.  I conclude that more care needs to be taken to fully
and properly inform vulnerable populations of their fertility preservation
options.  Detailed information provided to each and every patient will
help build trust in the medical system that is needed to address medical
and cancer disparities that exist in minority populations.  Additionally, I
identify other related legal issues that should be rolled into the informed
consent procedure to avoid dispositional dilemmas.
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FERTILITY PRESERVATION FOR MEDICAL REASONS AND REPRODUCTIVE
JUSTICE
Orla McManus was eighteen months old when she had to undergo
chemotherapy in Australia.2  Understandably, her parents were worried
about her health and survival—but they were also worried about her fu-
ture fertility.3  Despite the fact that she was so young, her parents began
exploring options to save their daughter’s fertility.4  They came across a
procedure where doctors could harvest one of her ovaries, freeze the tis-
sue, and later graft it back into Orla when she decided to have children
during adulthood.5  They met with a group of doctors in Melbourne who
agreed to remove one of Orla’s ovaries to preserve her future fertility.6
Although there have been only a handful of pregnancies worldwide us-
ing grafted ovarian tissue (and one live birth to date7), Orla’s parents
wanted to give her a chance to have a baby when she grows up, assuming
she survives her disease.8
Stories such as Orla’s are going to become increasingly common due
to the growth of fertility preservation for medical reasons.  There has been
great focus on oncofertility,9 an interdisciplinary field that bridges the gap
2. See Lucie Van Den Berg, Orla McManus Has Had a Ground-Breaking Operation So She
May Be a Mother One Day, HERALD SUN, (July 20, 2013, 9:24 PM), http://www.herald
sun.com.au/news/victoria/orla-mcmanus-has-had-a-ground-breaking-operation-
so-she-may-be-a-mother-one-day/story-fni0fit3-1226682509574.
3. See id.
4. See id.
5. See id.
6. See id.  The Royal Children’s Hospital gynecology team, who had never removed an
ovary for fertility preservation from a patient so young, agreed to do the procedure
due the minimal additional risk to Orla’s health. See id. Orla was already under
anesthesia for a different medically necessary procedure, and the ovary removal
was done through a laparoscopic operation. See id.
7. See Kate Waimey Timmerman, Research Update: First Live Human Birth From Vitrified
Ovarian Tissue, ONCOFERTILITY CONSORTIUM BLOG (Oct. 2, 2013), http://blog.oncofer
tility.northwestern.edu/2013/10/research-update-first-live-human-birth-from-vitri
fied-ovarian-tissue-2/.
8. See Van Den Berg, supra note 2.  The ovary was harvested and cut into tiny slices. R
See id.  The ovarian tissue was frozen and stored until Orla decides to try to start a
family as an adult. See id.  If she does, the tissue will be grafted back into her pelvic
wall. See id. In the ideal situation, the grafted tissue will start to function and pro-
duce mature eggs, which will be removed and fertilized using in vitro fertilization.
See id.  In some cases, spontaneous pregnancy may occur after grafting. See id.
9. This Article uses the term “fertility preservation for medical reasons” because it
includes those who may face infertility for reasons other than cancer.  However, the
term “oncofertility,” coined by Dr. Teresa Woodruff, is often used to refer to fertility
preservation for medical reasons. See About the Oncofertility Consortium, THE
ONCOFERTILITY CONSORTIUM, http://oncofertility.northwestern.edu/about-us (last
visited Mar. 13, 2014).  In 2005, reproductive endocrinologist Dr. Teresa Woodruff
founded the Oncofertility Consortium and Reproductive Endocrinology and Infer-
tility Clinic at Northwestern University. See Jessica Reaves, Miracle Workers, CRAIN’S
CHI. BUS., Apr. 1, 2013, at 23.  The structure of the consortium serves to discuss
fertility options for patients undergoing cancer treatment. See id. Dr. Woodruff em-
phasizes the importance of discussing cancer treatments and fertility “in the same
breath.” Id. Due to her policies, more than seventy-five percent of cancer patients
at the Northwestern Memorial Hospital have learned about ways to save their fertil-
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between oncology and reproductive medicine.10  As survival rates for can-
cer patients have increased over the past decades, young patients as well
as adults are able to live full lives after cancer.11 However, survivors often
face infertility as a result of the cancer or the treatment itself.12 Each pa-
tient reacts differently to treatment, and both the time available before
treatment is required and the impacts of that treatment on fertility may
vary.13
Fertility preservation options must be based on the patient’s unique
circumstances, which may be affected by a variety of issues: patient’s age,
marital status, religious or cultural constraints, and overall prognosis, for
example.14  Several traditional options as well as some newer technologi-
cal options are available now for those cancer survivors who wish to have
a child.15  Traditional options include adoption and surrogacy, which, al-
though allowing for a family, do not allow the women the opportunity to
reproduce genetically related offspring.16  Fertility preservation through
the use of technology already exists for men and boys, including cry-
opreservation of semen for later intrauterine insemination.17  For women,
there currently exists the option to stimulate the ovaries to help eggs ma-
ture for retrieval and later fertilization.18 However, this option often re-
quires the delay of cancer treatments during the hormonal stimulation of
the ovaries, and prepubescent girls are often not eligible for these proce-
dures due to the immature state of their reproductive organs.19  In addi-
tion, there is the potential for certain cancers to react negatively to the
hormones themselves.20  Thus, the field of oncofertility is trying to find
ity.  See id. So far, sixty-two cancer treatment centers in the United States and ten
worldwide have adopted the same procedures.  See id.
10. See About the Oncofertility Consortium, THE ONCOFERTILITY CONSORTIUM, http://
oncofertility.northwestern.edu/about-us (last visited Mar. 13, 2014).  There have
been stories of successful fertility preservation in the press lately. See, e.g., Jessica
Reaves, Miracle Workers, CRAIN’S CHI. BUS., Apr. 1, 2013, at 23.  One such story is that
of Nicole Torrillo, who was diagnosed with ductal carcinoma at the age of 35.  She
and her husband did not yet have children and as a part of her cancer treatment,
she was advised of her fertility preservation options.  With the help of egg freezing
and in vitro fertilization, Torrillo was able to have a biological child three years after
her cancer treatment. See id.  As recently as 2005, cancer treatment options did not
take into account future family planning or fertility options. See id.  However, due
to advances in modern science, Torrillo was able to secure her fertility despite un-
dergoing cancer treatment that would leave many unable to have biological chil-
dren. See id.
11. See About the Oncofertility Consortium, THE ONCOFERTILITY CONSORTIUM, http://
oncofertility.northwestern.edu/about-us (last visited Mar. 13, 2014).
12. See id.
13. See Fertility Options, THE ONCOFERTILITY CONSORTIUM, http://oncofertility.northwest
ern.edu/patients/fertility-preservation-options-nu (last visited Mar. 13, 2014).
14. See id.
15. See Gregory Dolin et al., Medical Hope, Legal Pitfalls: Potential Legal Issues in the
Emerging Field of  Oncofertility, 49 SANTA CLARAL. REV. 673, 683 (2009).
16. See id. at 683–84.
17. See id. at 684.
18. See id.
19. See id.
20. See id. at 685.
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new methods to both improve awareness and help find new techniques
for preserving fertility.21
As advances in fertility preservation for medical reasons are made, as
in other areas of reproductive technology, a number of legal and ethical
issues arise.22  Fertility preservation for medical reasons involves the con-
stitutional rights of women, minors, and men to bear children, their right
to use assisted reproductive technology (ART), as well as feminist con-
cerns about pressures on women to use these very technologies.23  The
right to reproduce is protected under both American and international
law, having been reaffirmed by the United States Supreme Court24 and
the United Nations Universal Declaration of Human Rights, among other
international covenants and conventions.25
Part I of this Article provides a description of the science of oncofer-
tility, how cancer treatment affects fertility and how fertility can be pre-
served.  Part II of this Article focuses on physician practice patterns
21. See id. at 686.
22. See id. at 675.
23. See id.
24. See id. at 676.
25. See id. at 677.  However, it is less clear whether the right to ART is as well protected.
See id. at 678.  Although no courts have explicitly recognized a constitutional right
to assisted reproduction, it would seem that the United States law “takes for
granted that such a right exists.” Id.  Individual states, as well as the federal gov-
ernment, have adopted statutes implicitly recognizing the legality of in vitro fertili-
zation (IVF). See id. at 678–79.  Although these statutes do not explicitly protect the
rights to IVF, they at least acknowledge that such a right exists and recognize the
state and federal powers to regulate them. See id. at 679.  The balance between the
governmental power to regulate and the right to procreate is still unclear. See id.
Courts in both in the United States and abroad have acknowledged a right to use
ART, having adjudicated cases involving ownership of embryos subject to ART. See
id.  Although not explicitly noting the existence of such a right, the courts adjudi-
cated the cases by simply treating ART as a legal means of reproduction. See id. at
680.  Protections of the right to use ART have already been somewhat limited, as
some courts have refused to enforce surrogacy contracts as against public policy,
and some states have exempted insurance companies from having to cover IVF or
other forms of ART. See id.  Further, public medical assistance programs in many
states do not cover infertility treatments. See id.  In addition, women’s use of vari-
ous reproductive technologies is controversial as well. See id. at 681.  Some argue
that ARTs enhance a woman’s choices for reproduction, while others argue that
restoring fertility to female cancer patients simply puts them on equal footing with
men, who can more easily store sperm for use in the future. See id.  At the same
time, others argue that ART “reinforc[es] unjust expectations about women’s repro-
ductive roles,” and that some women feel the duty to under go such processes to
avoid the stigma of not being able to reproduce. Id.  Because oncofertility also
works to ensure reproductive capabilities of young cancer survivors, the rights of
minors to reproduce are also implicated. See id. at 682.  While minors generally
have the same reproductive rights as their adult counterparts, states have greater
power to regulate these rights. See id.  Although the Supreme Court of the United
States has been more open to allowing adult involvement in a minor’s decision to
have an abortion, it has never allowed a parent to entirely veto such decision. See
id.  Additionally, the age of consent for a person to bear children is below the age of
majority in many states, and parents cannot deprive a minor of their future repro-
ductive ability without a court order requiring a showing of compelling need. See
id.  Overall, minors have the same constitutional protections as adults when it
comes to reproduction. See id. at 683.
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related to providing information to cancer patients about fertility preser-
vation options.  Part III focuses on the American Medical Association
(AMA) policy to advocate for insurance coverage of fertility preservation
for medical reasons and state efforts to require such insurance coverage.
Part IV of this Article reviews these policies and efforts through a repro-
ductive justice framework to examine whether such policies even the
playing field or whether they exacerbate the inequities in the health sys-
tem.  Finally, Part V of this Article concludes with next steps and addi-
tional legal issues that must be dealt with in this emerging medico-legal
field.
I. THE SCIENCE OF ONCOFERTILITY
Oncofertility refers to the process of preserving the fertility of women
(and men) who need to undergo cancer treatments that may cause re-
duced fertility (or sterility).  This process typically involves counseling a
patient about the potential fertility consequences of their cancer treat-
ment, and then if a patient so chooses (and can afford it) freezing the eggs
(or sperm) to potentially use later using in vitro fertilization or using a
gestational surrogate.  As cancer survival rates improve, the ability to
bear children after therapy is increasingly a concern for many patients.
Some patients may choose their cancer therapy based on the risk of fertil-
ity loss rather than on its effectiveness to cure the cancer.  Unfortunately,
a patient’s race and insurance status often determines if and when they
are told about the fertility consequences of their treatment.  Those with-
out insurance are often in dire straits after a cancer diagnosis, so physi-
cians may not inform them about fertility preservation due to the high
costs.  In one study, four percent of women medically eligible for fertility
preservation actually underwent the process.26 Many options within the
field of oncofertility are still experimental—especially the options for wo-
men and girls not yet of reproductive age.27  These include whole ovary
and oocyte cryopreservation as well as the freezing of ovarian tissue.28
For boys not yet of reproductive age, and thus unable to freeze semen,
investigational options include the freezing of testicular tissue.29
Chemotherapy agents and radiation therapy often result in
gonadatoxicity, which can impair both male and female reproductive ca-
26. See Joseph M. Letourneau et al., Racial, Socioeconomic, and Demographic Disparities in
Access to Fertility Preservation in Young Women Diagnosed with Cancer, 118 CANCER
4579, 4583 (2012), available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.266
49/full.  Since 1998, the federal Woman’s Health and Cancer Rights Act mandates
that insurers cover breast reconstruction if they covered the mastectomy and in fact,
treatment of almost every side effect from cancer treatment is covered by insurance
except for fertility preservation.  Dolin, supra note 15 at 683. R
27. See Ina N. Cholst, Oncofertility: Preservation of Reproductive Potential, 61 DEPAUL L.
REV. 763, 766 (2012).
28. See Mary E. Fallat & John Hutter, Preservation of Fertility in Pediatric and Adolescent
Patients with Cancer, 121 PEDIATRICS e1461, e1463 (2008); Pasquale Patrizio & Arthur
L. Caplan, Ethical Issues Surrounding Fertility Preservation in Cancer Patients, 53
CLINICAL OBSTETRICS & GYNECOLOGY 717, 718 (2010).
29. See Fallat, supra note 28. R
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pabilities.30  Also, some patients may require oophorectomy, or egg re-
moval, for various benign and malignant conditions.31  If a girl is past the
stage of puberty, her eggs can be banked and frozen for her future use via
in vitro fertilization.32  The American Society of Reproductive Medicine
determined that such egg freezing was no longer an experimental proce-
dure.33  Freezing eggs and sperm have been good options for postpubertal
cancer patients or other patients unable or not wishing to cryopreserve
embryos.34  However, to date, there have been no long- or even short-
term studies on the viability of ovarian tissue cryopreservation.  Because
the population being offered fertility preservation is suffering from can-
cer, the predicted prognosis of the patient will determine whether fertility
preservation is a viable option.  If the cancer must be treated immedi-
ately, there may be no time to delay treatment to undergo fertility preser-
vation.  Because African Americans often have their illness detected at a
later stage than other populations, their prognosis is often worse.35  Other
limitations to use of this technology include age, cost, and how available
it is in the patient’s area.36
Fertility often cannot be spared when reproductive organs must be
entirely removed, when the radiation field is located such that reproduc-
tive organs cannot be shielded, or when chemotherapy must be adminis-
tered directly to the reproductive organs of either male or female
patients.37  The most common reason for decreased fertility after cancer
treatment is due to exposure to uterine radiation, hypothalamic/pituitary
radiation, or alkylating agent chemotherapy.38  One study has shown that
30. See The Practice Comms. of the Am. Soc’y for Reprod. Med. and the Soc’y for As-
sisted Reprod. Tech., Mature Oocyte Cryopreservation: A Guideline, 99 FERTILITY AND
STERILITY 37 (2013) [hereinafter “The Practice Committees”].
31. See id. at 41.
32. See id. at 39.  “Data on pregnancy and live births from oocyte cryopreservation in
cancer patients are very limited, and success rates must be extrapolated from other
populations for patient counseling. However, in this population at high risk for in-
fertility, oocyte cryopreservation may be one of the few options available and there-
fore is recommended with appropriate counseling.” Id. at 41.
33. See id. at 41.
34. See id.
35. Stacey A. Missmer et al. . Cultural Factors Contributing to Health Care Disparities
Among Patients with Infertility in Midwestern United States, 95 FERTILITY & STERIL-
ITY 1943, 1943 (2011).
36. See id.
37. See Cholst, supra note 27, at 764.
38. See Daniel M. Green et. al., Fertility of Female Survivors of Childhood Cancer: A Report
from the Childhood Cancer Survivor Study, 27 J. OF CLINICAL ONCOLOGY 2677, 2681
(2009), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690392/.
There have been several studies on fertility preservation in breast cancer patients.
When discussing fertility preservation for medical reasons, it is important to note
that improved early detection and treatment has increased the likelihood that wo-
men diagnosed with early-state breast cancer will survive their disease. See Pamela
N. Munster, Fertility Preservation and Breast Cancer: A Complex Problem, CANCER NET-
WORK (June 17, 2013), http://www.cancernetwork.com/display/article/10165/
2145852.  Whether a girl or woman will become infertile during treatment depends
on many factors including patient’s age at diagnosis, the type and dose of regimen
used, genetic predisposition, and lifestyle factors. See id. An increasing number of
young patients with breast cancer have never conceived or completed family plan-
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although cancer survivors take a longer time to get pregnant, sixty-four
percent of them with self-reported infertility achieved a pregnancy.39  This
study brings some hope that cancer survivors may be able to become
pregnant even without fertility preservation.40
Amenorrhea, or a lack of menstruation related to cancer therapy, can
also lead to fertility problems.  This symptom is dependent on agent used,
dose, and duration of therapy and is strongly associated with advancing
age.41  Some studies show that chemotherapy-induced amenorrhea could
be considerably reversed in time.42
ning at diagnosis of breast cancer.  See id.  Age at diagnosis and at the anticipated
completion of therapy of breast cancer are the most important natural factors when
considering fertility preservation, especially when there are an increasing number
of children born to women over the age of 35. See id.  Fifteen out of one thousand
children in the United States were born through the use of assisted reproductive
technology (ART) in 2011, assisting in the delayed onset of childbearing.  See id.;
Brady E. Hamilton et at., Births: Preliminary Data for 2011, NAT’L VITAL STATS. REPS.,
Oct. 3, 2012, at  1.  Fertility is strongly linked to the onset of menopause with a
steady decrease in ovarian reserve and fertility after age thirty, with a sharp drop
after age thirty-seven. See generally M.J. Faddy et al., Accelerated Disappearance of
Ovarian Follicles in Mid-Life: Implications for Forecasting Menopause, 7 HUMAN REPROD.
1342, 1342–46 (1992).  Underlying risk factors, like premature or early menopause
(before age 45) impacted by family history, smoking, ethnicity, and socioeconomic
status, should be considered in each patient with assessing risk of chemotherapy-
induced amenorrhea and the potential for successful fertility preservation. See gen-
erally Ellen B. Gold et al., Factors Associated with Age at Natural Menopause in a Mul-
tiethnic Sample of Midlife Women, 153 AM. J. EPIDEMIOLOGY 865, 865–74 (2001).
39. See Green et al., supra note 38.  The Childhood Cancer Survivor Study (“CCSS”)
studied individuals who survived five or more years after a cancer diagnosis,
treated in twenty-seven different institutions, both in Canada and the United States.
See Learn More, CHILDHOOD CANCER SURVIVOR STUDY (CCSS), https://ccss.stjude
.org/about/learn-more (last visited Apr. 9, 2014).  Compared to their non-cancer
survivor siblings, the survivors had an increased risk of clinical infertility and less
likely to be prescribed drugs for treatment of infertility, despite being equally likely
to seek such drugs.  See Green et al., supra note 38.
40. See Green et al., supra note 38.  See also Stella M. Davies, Subsequent Malignant Neo-
plasms in Survivors of Childhood Cancer: Childhood Cancer Survivor Study (CCSS) Stud-
ies, 48 PEDIATRIC BLOOD CANCER 727 (2007); A.C. Mertens, Cause of Mortality in 5-Year
Survivors of Childhood Cancer, 48 PEDIATRIC BLOOD CANCER 723 (2007); Leslie L. Robi-
son, Treatment-Associated Subsequent Neoplasms Among Long-Term Survivors of Child-
hood Cancer: The Childhood Cancer Survivor Study Experience, PEDIATRIC RADIOLOGY,
Feb. 2009 (Supp. 1), at S32); Leslie L. Robison et al., The Childhood Cancer Survivor
Study: A National Cancer Institute-Supported Resource for Outcome and Intervention Re-
search, 27 J. CLINICAL ONCOLOGY 2308 (2009); Gregory T. Armstrong, Long-Term Sur-
vivors of Childhood Central Nervous System Malignancies: The Experience of the Childhood
Cancer Survivor Study, 14 EUROPEAN J. PEDIATRIC NEUROLOGY 297 (2010).
41. See Munster, supra note 38.
42. See id.  There was once concern over artificially creating high estrogen levels during
ovarian stimulation, but studies have suggested that ovarian stimulation can be
safely accomplished with aromatase inhibitors or tamoxifen, preventing high es-
tradiol peaks during ovarian stimulation. See id.; Kutluk Oktay et al., Fertility Preser-
vation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian
Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation, 23 J. CLINICAL
ONCOLOGY 4347, 4347–53 (2005).  This process can be completed within one men-
strual cycle, it is feasible prior to initiation of chemotherapy, and ART does not
require women to have a partner at the time of diagnosis to complete in vitro fertili-
zation (IVF) for a later pregnancy. See id. at 4348.  The delay of pregnancy may not
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Fertility preservation is an important topic, but even when physicians
discuss the risk of cancer therapy on fertility, patients are not referred to a
reproductive center with expertise in cancer because of perceived risks,
cost, and time constraints.43  The relevance of fertility preservation is not a
high priority upon diagnosis, but becomes more important once the pa-
tient’s prognosis improves.44 Another study determined that loss of fertil-
ity resulted in a detriment to patients’ quality of life, and counseling
about fertility loss and discussion of fertility preservation options re-
sulted in better long-term acceptance of fertility loss.45
II. CURRENT PRACTICE PATTERNS
Many oncologists are not following fertility preservation guidelines
and are unaware of current guidelines regarding fertility preservation for
cancer patients, according to the results of a survey presented at the
American Society of Clinical Oncology (“ASCO”) Annual Meeting.46  In
2006, ASCO issued guidelines regarding fertility preservation,47 which
recommended that oncologists “address the possibility of infertility with
patients treated during their reproductive years and be prepared to dis-
cuss possible fertility preservation options or refer appropriate and inter-
ested patients to reproductive specialists.”48  However, only 38% of the
surveyed physicians stated that they were aware of ASCO’s guidelines
regarding infertility.49  Among oncologist respondents, the majority (79%)
reported discussing fertility preservation with patients of childbearing
age, however, 75% of that group failed to refer such patients to reproduc-
tive specialists or distribute educational materials regarding fertility pres-
ervation.50  Although, according to one study, at least half of patients do
not recall receiving information about fertility from their physicians,51
there is wide variation in the information that is disseminated.  It can
be detrimental when donor oocytes or frozen embryos or oocytes are used because
only the age of the oocytes, but not the age of the uterus, appears to be a factor in
the ability to conceive. See Munster, supra note 38.  When using non-donor oocytes,
the rate of births resulting from ART is linked to age of the patient at time of har-
vest. See id.  When donor oocytes are used, age, ovarian reserve, and ovarian func-
tion are no longer limiting factors. See Barbara Luke et al., Cumulative Birth Rates
With Linked Assisted Reproductive Technology Cycles, 366 NEW ENG. J. MED. 2483,
2483–91 (2012).
43. See Gwendolyn P. Quinn et al., Discussion of Fertility Preservation with Newly Diag-
nosed Patients: Oncologists Views, 1 J. CANCER SURVIVORSHIP 146, 146 (2007).
44. See Munster, supra note 38.
45. See id.; Joseph M. Letourneau et al., Pretreatment Fertility Counseling and Fertility Pres-
ervation Improve Quality of Life in Reproductive Age Women With Cancer, 118 CANCER
1710, 1710 (2012).  Thus, just having a physician inform a patient of their fertility
preservation options seems to help, even when the patient does not utilize such
options. See id. at 1715.
46. See Roxanne Nelson, ASCO 2009: Fertility Preservation Guidelines Not Widely Followed,
MEDSCAPE.COM (June 1, 2009), http://www.medscape.com/viewarticle/703634.
47. See Stephanie J. Lee et. al., American Society of Clinical Oncology Recommendations on
Fertility Preservation in Cancer Patients, J. OF CLINICAL ONCOLOGY 2917, 2927. (2006).
48. Id. at 2917.
49. See Nelson, supra note 46.
50. See id.
51. See id. at 2926.
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range from a brief mention about the risk for infertility to an in-depth
discussion about the risks for impaired fertility and referrals to reproduc-
tive endocrinologists.  Physicians reported that the primary barrier to dis-
cussion was a patient being too ill to delay treatment.  Many respondents
also said that they did not discuss fertility preservation when they be-
lieved that the patient had a poor prognosis.52  Additionally, the ASCO
guidelines do not oblige physicians to discuss fertility preservation with
patients; they simply make the recommendation that physicians should
do so.
A concern often cited by physicians about why they do not always
discuss fertility preservation is the cost involved in trying to preserve fer-
tility.  Because insurance companies do not have to cover fertility preser-
vation for medical reasons, it is often an additional financial burden in an
already stressful time.  An important barrier identified by both patients
and clinicians is the high cost and the lack of insurance coverage for fertil-
ity preservation services.  In one study, researchers examined state poli-
cies regarding insurance coverage as it related to infertility in cancer
patients.  Although fifteen states have laws relating to insurance coverage
for infertility or IVF procedures, none of them have laws or regulations
addressing insurance coverage for fertility preservation methods specific
to cancer patients.53  Arguably, even in states that do not generally en-
dorse insurance coverage fertility preservation generally, there may be
more political will and empathy from the general public to require cover-
age for patients who lose their fertility due to cancer treatment.
One study showed that females, Blacks, and the uninsured were all
much less likely to be told about fertility preservation during the course
of their cancer therapy.54  Of these groups, it appears that females with
52. See Am. Soc’y for Reprod. Med., Fertility Preservation for Cancer Patients: Demographic
Disparities in Counseling and Financial Concerns are Barriers to Utilization,  IVF.NET
(Oct. 23, 2012), http://www.ivf.net/ivf/fertility-preservation-for-cancer-patients-
demographic-disparities-in-counseling-and-financial-concerns-are-barriers-to-utili-
zation-o6988.html.
53. See David Orentlicher, Discrimination out of Dismissiveness: The Example of Infertility,
85 IND. L.J. 143, 168–69 (2010).
54. See Margarett Shnorhavorian et al., Fertility Preservation Among Adolescent and
Young Adult Cancer Survivors in the AYA Hope Study, American Urological Asso-
ciation National Meeting, Society of Pediatric Urology (May 3, 2013), available at
http://www.spuonline.org/abstracts/2013/8.cgi. One study examined adoles-
cents and young adults (“AYA”) with cancer and the devastating effect that treat-
ment could have on future fertility. See Overview and Key Objectives, ADOLESCENT &
YOUNG ADULT HEALTH OUTCOMES & PATIENT EXPERIENCE STUDY (AYA HOPE) (last
updated Sept. 13, 2013), http://appliedresearch.cancer.gov/surveys/aya/over-
view.html. Funded by the National Cancer Institute and the Lance Armstrong Foun-
dation, the facilitators of this study, called the AYA HOPE Study, investigated
factors associated with fertility preservation and cancer treatment effects on the fe-
male reproductive system. See id. 484 patients, male and female, all diagnosed with
cancer between 2007 and 2009, were told by their healthcare providers that cancer
treatments may affect their fertility. See Shnorhavorian, supra note 54. In addition,
they all discussed fertility preservation options with their doctors and made ar-
rangements for such. See id. The issue to be determined was whether fertility pres-
ervation measures were associated with demographic characteristics such as race
and marital status, and socioeconomic factors such as education and employment
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government insurance were at the highest risk for not having discussions
about fertility preservation.55  Not surprisingly, uninsured status was a
predictor for not making preservation arrangements prior to starting can-
cer treatment within all of the groups.56
Another study similarly found that many cancer patients may not be
receiving counseling about their treatment’s potential to affect their long-
term reproductive health and that demographic disparities exist between
those who receive counseling and those who do not.57  Factors that influ-
enced who got counseling and who did not included education level,
whether or not the women had children, and insurance status.58  Women
who had already had children at the time of their treatment were half as
likely to be counseled about fertility preservation as those who were
childless.59  Just because a woman has already had a child does not mean
that she should not be counseled about the option to preserve her fertility
should she decide to have additional children.  The patient should make
this decision, not the physician.  However, it appears that physicians are
either consciously or subconsciously withholding this information from
women who have already had children prior to their cancer diagnosis.
Women who had bachelor’s degrees were twice as likely to be counseled
as those without a degree and women with private insurance were three
times more likely to receive counseling than the uninsured.60
An additional survey-based investigation suggests “that a lack of
money is the biggest barrier preventing women with cancer who have
received counseling on fertility preservation from following through with
it.”61  Ninety percent of women surveyed who had received counseling
reported at the time for decision-making that cost and lack of insurance
coverage were their reasons for not utilizing fertility preservation tech-
nologies.62  Additional surveys have found that men are generally coun-
seled in fertility preservation less frequently than women, with only 30%
of clinics surveyed even offering counseling to male patients.63  Prelimi-
nary results show that, of patients who received cancer treatment with
status. See id. Provider and hospital features were also taken into consideration.
See id.
55. See id.
56. See id.
57. Am. Soc’y for Reprod. Med., supra note 52 (the survey was mailed to 2300 women
from the California Cancer Registry who had been diagnosed with a gynecologic
cancer between 1993 and 2007 and aged18 to 40 at time of their diagnosis).
58. See id.
59. See id.
60. See id.
61. Id. (citing Joseph M. Letourneau et al., Sociodemographic Disparities Affect Access to
Reproductive Health Counseling Among Reproductive Age Women Undergoing Gyneco-
logic Cancer Treatment, FERTILITY & STERILITY, Sept. 2012 (Supp.), at S121.  The aver-
age cost for oocyte cryopreservation is $6608; embryo cryopreservation, $8285;
sperm cryopreservation, $244; and sperm storage, $381 annually. See id. (citing Erin
E. Niemasik et al., It All Comes Down to Money: Why Women Decide Not to Un-
dergo Fertility Preservation, American Society for Reproductive Medicine (Oct.
2012).
62. See id.
63. See id.
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the power to impact their fertility, only 50% were counseled by their on-
cology team about those risks, and only 3% underwent fertility
preservation.64
III. EFFORTS TO PROMOTE FERTILITY PRESERVATION FOR MEDICAL
REASONS
AMA Policy on Fertility Preservation in Cancer
In June 2013, the American Medical Association adopted a policy
“support[ing] coverage by all insurance providers of fertility preservation
therapies for patients requiring cancer treatments that may result in infer-
tility.”65  Currently insurers do not routinely cover these fertility treat-
ments, which the AMA says, “should be an essential part of the
management of [a patient’s] cancer.”66  In addition, the new policy sup-
ports lobbying for federal legislation.67  The new policy would essentially
treat infertility as a side effect of treatment or as a condition unto itself
created by cancer.68  Thus, it is not the patient solely choosing to undergo
infertility treatments for their own sake, but rather the need for the treat-
ments is a result of the medical condition.
Other Medical Associations’ Policies
The guidelines from the National Comprehensive Cancer Network
and the American Society of Clinical Oncology similarly note that infertil-
ity from cancer treatments must be discussed and the fertility preserva-
tion should be offered to anyone affected by those treatments.69
Some advocates for insurance coverage for fertility preservation com-
pare it to mandated insurance coverage for breast reconstruction after
breast cancer.70  The Women’s Health and Cancer Rights Act of 1998 man-
dated that if insurers covered mastectomy, then they must also cover
breast reconstruction.71  Every side effect of cancer treatment is covered
64. See id.
65. Press Release, Am. Med. Ass’n, AMA Adopts New Policies on First Day of Voting at
Annual Meeting (June 17, 2013), available at http://www.ama-assn.org/ama/pub/
news/news/2013/2013-06-17-new-ama-policies-annual-meeting.page [hereinafter
AMA Press Release].
66. Id.
67. See Angela Krausfeldt, Support for Fertility Preservation is Now an AMA Policy!,
ONCOFERTILITY CONSORTIUM BLOG (June 28, 2013), http://blog.oncofertility.north
western.edu/2013/06/support-for-fertility-preservation-is-now-an-ama-policy/.
68. See id.
69. See Raphael Yechieli, Triaging Fertility Preservation & the AMA, TRIAGE CANCER BLOG
(July 1, 2013), http://triagecancer.org/blog/triaging-fertility-preservation-the-
ama/; Stephanie J. Lee et al., American Society of Clinical Oncology Recommendations
on Fertility Preservation in Cancer Patients, 24 J. OF CLINICAL ONCOLOGY 2917 (2006)
(advocating that, as a part of treatment discussions and informed consent, fertility
preservation options should be discussed by the oncologist, or the patient should be
referred to a reproductive specialist).
70. See Yechieli, supra note 69.
71. See id.
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by insurance except for infertility—often because the individual has not
yet been “diagnosed with infertility.”72
Several arguments may be made as to why breast reconstruction and
other conditions resulting from cancer, such as hair loss, should be
treated differently as compared to the treatment for infertility.73  First,
several ARTs are still considered experimental, and insurers generally do
not cover experimental procedures.74  Alternately, breast reconstruction is
already considered an established procedure.75 Second, most insurance
companies cover conditions that currently exist or that have a more clear
certainty of existing.76  Because infertility is only a future possibility, and
the chances that some patients will even experience infertility may be
low, most insurance companies are unlikely to cover the procedures.77  In
addition, even after a patient undergoes most methods used to preserve
fertility, such as cryopreservation, the embryos, eggs or ovarian tissue
may not actually be used for some time into the future.78  Third, items
such as breast reconstruction or wigs are often covered by insurance be-
cause they are visible to the patient and those around them, and are thus
seen as necessary to help normalize the patient’s physical body and gen-
der.79  Fourth, fertility preservation is a more complex issue than other
side effects or conditions because it ultimately affects not just the patient,
but also their partner, family and future offspring.80  This is especially
complex in cases where family members seek to use preserved eggs,
sperm or embryos may be used for posthumous reproduction, after a can-
cer patient loses his or her battle against the disease.
To counter these potential arguments against coverage of fertility
treatments, it can be argued that many in the scientific community no
longer consider many fertility preservation treatments to be experimen-
tal.81  In fact, as the American Society for Reproductive Medicine con-
cluded that oocyte cryopreservation “should no longer be considered
experimental.”82  Egg freezing is also now more commonplace, with up to
70–90% of eggs surviving the freeze-thaw process.83
Additionally, just because infertility may not be immediate and may
not affect a patient until years down the road when they are prepared to
72. Id.
73. See Lisa Campo-Engelstein, Insurance Coverage for Cancer Treatment-Induced Condi-
tions: Comparing Fertility Preservation Technology and Breast Reconstructive Surgery, 61
DEPAUL L. REV. 849, 855 (2012).
74. See id at 856.  Currently, fertility preservation techniques are in the experimental
stage.  However, even if they become more established, insurance companies do not
cover fertility preservation. However, some ART clinics do offer discounts to cancer
patients, compared with other infertile patients.
75. See id.
76. See id.
77. See id.
78. See id.
79. See id. at 857.
80. See id.
81. See id. at 856.
82. See The Practice Committees, supra note 30, at 37. R
83. See id. at 39.
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start a family, it does not make the harm any less real or significant.84
Further, while breasts and hair are visible signs of femininity, pregnancy
and the bearing of children can be considered the ultimate sign of femi-
ninity.85  And, finally, insurance companies already cover other proce-
dures that have complex implications for those other than simply the
patient—fetal surgery, including “corrective” surgery for intersex infants,
and genetic testing for hereditary diseases.86  The complexity of the issue
should not mean that a patient is precluded from coverage, but simply
that additional counseling and assistance be provided.87
Bills Mandating Insurance Coverage of Fertility Preservation
Although no states currently have laws requiring insurance coverage
for fertility preservation for medical reasons, as of January 2013, the fol-
lowing states mandate insurance coverage for general infertility treat-
ments—Arkansas, California, Connecticut, Hawaii, Illinois, Louisiana,
Maryland, Massachusetts, Montana, New Jersey, New York, Ohio,88
Rhode Island, Texas, and West Virginia.89  These laws are often inconsis-
tent in terms of what type of infertility services are covered, whether mar-
ital status is an issue, and whether there is a maximum age of coverage.90
Only Connecticut, Illinois, Maryland, Massachusetts, Montana, New
Jersey, Ohio, and West Virginia require insurers to cover IVF at the time
of this writing.  California law mandates that some insurance coverage at
least be offered to cover infertility treatments, but does not require IVF to
be covered.91  Massachusetts’ mandate, although not specifically aimed at
84. See Campo-Engelstein, supra note 73, at 857. R
85. See id.
86. Id.
87. See id.
88. OHIO REV. CODE ANN. § 1751.01 (A) (1)(h) (West 2013) (requiring health mainte-
nance organizations (HMOs) to provide infertility services, when medically neces-
sary).  It is not at all clear how medically necessary would be interpreted when
someone needs to undergo chemotherapy and may face infertility as a result.  It is
unclear and arguably unlikely that insurer would consider it medically necessary
for such a patient to receive fertility preservation services prior to the
chemotherapy.
89. State Laws Related to Insurance Coverage for Infertility Treatment, NAT’L CONFERENCE OF
STATE LEGISLATURES, http://www.ncsl.org/issues-research/health/insurance-cov-
erage-for-infertility-laws.aspx (last updated Mar. 2012). See also Ark. Code Ann.
§§23-85-137 (West 2011), 23-86-118 (West 2012); CAL. HEALTH & SAFETY CODE
§1374.55 (West 2012); CAL. INS. CODE §10119.6 (West 2012); CONN. GEN. STAT. §38a-
536 (2013); HAW. REV. STAT. §431:10A-116.5(a) (2012); MASS. GEN. LAWS ANN. ch.
175, §47H (West 2010), 176A §8K (West 2010), 176B §4J (West 2010), 176G §4 (West
2011); MD. CODE ANN., INS. §15-810 (West 2012); MONT. CODE ANN. §33-31-102 (West
2011); N.J. STAT. ANN. §17B:27-46.1x (West 2001); N.Y. INS. LAW §§3221(k)(6), 4303(s)
(McKinney 2012); OHIO REV. CODE ANN. §1751.01 (West 2012); R.I. GEN. LAWS §§27-
18-30, 27-19-23, 27-20-20, 27-41-33 (2012); TEX. INS. CODE ANN. art. 1366.005 (West
2005); W. VA. CODE §33-25A-2 (2010).
90. See Briana K. Fundalinski, Limitations on Insurance Coverage For Fertility Treatment:
Arguments For & Against Capping the Age & Restricting the Marital Status, 23 Alb. L.J.
Sci. & Tech. 625, 629.
91. See, e.g., CAL. HEALTH & SAFETY CODE § 1374.55; CAL. INS. CODE § 10119.6 (specify-
ing insurance for certain forms of infertility treatment, but not IVF); Susan T
Vadaparampil, State Laws and Regulations Covering Fertility Preservation for Cancer Pa-
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infertility due to cancer treatments or other medical diagnoses, is a bit
more flexible than other states in that it has a built in review system that
allows additional infertility procedures to be covered as they move from
research phases into routine procedures.92
Many states do not clearly define what is meant by infertility.93  For
those states that do define infertility—California, Connecticut, Illinois,
Massachusetts, New Jersey, New York, and Rhode Island—all definitions
include the inability to conceive after a year or more of sexual relations.94
Therefore, in order to be covered by insurance, individuals must have
been trying to conceive.  Further, other definitions include requirements
that the individual be married, have different timeframes for men and
women, or require specific diagnosis by physician of a condition as the
cause of the infertility.95  Even the definition of infertility from the Ameri-
can Society for Reproductive Medicine is limited to those who have been
unable to conceive after having engaged in consistent unprotected sex for
one year.96  The World Health Organization similarly defines infertility as
“[a] disease of the reproductive system defined by the failure to achieve a
clinical pregnancy after 12 months or more of regular unprotected sexual
intercourse,” as does the National Institute of Health.97  Thus, even where
insurance coverage may be mandated for fertility treatments, it does not
necessarily cover patients with cancer who are seeking fertility preserva-
tion prior to treatment.  These patients have not been unable to conceive
yet and because fertility preservation seeks to prevent a future and not
present harm, without a definitional change, these patients would likely
not be considered infertile under these laws.
Connecticut,98 Hawaii,99 New Jersey,100 and California101—as well as
the United States Congress102 have had bills pending relating to insurance
coverage fertility preservation specifically relating to patients with cancer
or cancer treatments.  California’s bill was approved by the assembly in
May 2013 and was set to be heard by the senate in July 2013.103  Califor-
nia’s bill would require a health care service plan and a health insurer to
tients, 2009 ASCO ANNUAL MEETING (Sept. 21, 2013), http://meetinglibrary.asco
.org/content/35754.
92. See Daniel Basco et al., Insuring Against Infertility: Expanding State Infertility Mandates
to Include Fertility Preservation Technology for Cancer Patients, 38 J. L. MED. & ETHICS
832, 833 (2010).
93. See Vadaparampil, supra note 88.
94. See id.
95. See id.
96. See Basco et. al., supra note 89, at 832.
97. Id. at 834.
98. H.B. 5644, Gen. Assemb., Jan. Sess. (Conn. . 2013).
99. H.B. 2105, 26th Leg., Reg. Sess. (Haw. 2012).
100. A.B. 2479, 215th Leg., 1st Sess. (N.J. 2012).
101. A.B. 912, 2013-2014 Assemb., Reg. Sess. (Cal. 2013).  An identical version of this
proposed legislation was struck down in 2011.  See A.B. 428, 2011-2012 Assemb.,
Reg. Sess. (Cal. 2011); see also Lisa Campo-Engelstein, Insuring Against Infertility,
TRIAGE CANCER BLOG (Aug. 20, 2012), http://triagecancer.org/blog/insuring-
against-infertility/.
102. H.R. 1851, 113th Cong. (2013). S. 881, 113th Cong. (2013).
103. See Krausfeldt, supra note 64.
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provide, on a large group basis, coverage for medically necessary ex-
penses for standard fertility preservation services “when a necessary
medical treatment may directly or indirectly cause iatrogenic infertility to
an enrollee or insured.”104
Although some may laud the goal of insurance coverage for fertility
preservation, these legislative efforts raise many questions about who
will benefit from these laws.  What about those without insurance?  Will
this exacerbate the gap between the insured and uninsured (or underin-
sured) even more?  Will minorities and the poor even benefit from this
technology?  Is it more likely that richer white cancer patients will be able
to preserve their biological connections to future children via fertility
preservation while minority cancer patients may faced with fewer repro-
ductive options?  In the next Part of this Article, I analyze these issues
through a reproductive justice framework to try to answer these ques-
tions in a thoughtful and inclusive manner.
IV. A REPRODUCTIVE JUSTICE ANALYSIS OF FERTILITY PRESERVATION FOR
MEDICAL REASONS
This Article has thus far described medical advances, regulatory ef-
forts, and medical group policies promoting fertility preservation for
medical reasons.  This Part analyzes whether this new technology should
be promoted and whether its normative use should be an ideal.  I use a
reproductive justice framework to highlight that policies and legal re-
quirements advocating fertility preservation education amongst cancer
patients do not affect all individuals equally.  Minorities, African-Ameri-
104. A.B. 912, 2013-2014 Assemb., Reg. Sess. (Cal. 2013).  The fiscal effect of AB 912 was
analyzed by the fiscal committee and reported on May 25, 2013. AB 912 Assembly
Bill – Bill Analysis, OFFICIAL CALIFORNIA LEGISLATIVE INFORMATION, http://www.leg
info.ca.gov/pub/13-14/bill/asm/ab_0901-0950/ab_912_cfa_20130525_030716_asm
_floor.html (last visited Apr. 9, 2014).  They found that the bill will result in approxi-
mately $69,000 of additional costs to the California Public Employees’ Retirement
System for additional premiums and unknown costs, potentially greater than
$100,000, to Covered California, to the extent the fertility treatment preservation
services exceed the Essential Health Benefits (EHB) requirement under the Afforda-
ble Care Act (ACA). See id.  Mandated-benefit laws require an insurer to provide a
certain kind of benefit to cover a specified illness or procedure whenever someone
purchases a certain kind of insurance. See Metro. Life Ins. Co. v. Massachusetts, 471
U.S. 724, 728 (1985).  When legislation enacts mandated-benefit laws, issues of pre-
emption emerge.  It is likely that these mandated-benefit laws would not be pre-
empted by either the federal Employee Retirement Income Security Act of 1974
(ERISA) or the National Labor Relations Act (NLRA).  The Supreme Court and Sixth
Circuit have seen cases similar to the one at bar, ruling on legislature requiring
health insurance providers to provide minimum health benefits. See id. at 727–28.
The Sixth Circuit found a statute requiring every insurer to offer health insurance
policies within the state to provide coverage for substance abuse to be a mandated-
benefit law. See Mich. United Food & Comm. Workers Unions v. Baerwaldt, 767
F.2d 308, 310, 312 (6th Cir. 1985).  It would be undisputed within the courts that the
new AMA policy and the California bill would both be considered mandated-bene-
fit laws.  Legislation that requires insurance providers to provide the benefit of fer-
tility preservation therapies will likely be considered a mandated-benefit law, just
as requiring insurers to provide mental health care and substance abuse was found
to be in the Supreme Court and the Sixth Circuit.
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cans especially, have poorer rates of cancer survival than whites.  Because
fertility preservation counseling is left up to the discretion of the physi-
cian, often those with poorer prognoses, such as African-Americans, are
not informed of their choices.  I hope to identify the gaps that exist in
current proposals and suggests areas of focus for fertility preservation for
medical reasons.
What is Reproductive Justice?
About three decades ago, the reproductive justice movement began as
a response to the feminist conception of reproductive rights as being
“pro-choice.”105  Women of color in the United States who were working
with grassroots feminist organizations spearheaded the effort to align re-
productive rights with social justice—and acknowledge that often poor,
women of color do not have the same choices as other women.106 Sister-
Song Women of Color Reproductive Health Collective, coined the term
“reproductive justice,” and was modeled upon global women’s health
movements.  Reproductive justice takes as its starting point women’s real-
life experiences with reproductive oppression in their communities.  Such
oppression includes history of forced sterilization, high-risk contracep-
tion, and environmental factors that resulted in diminished reproductive
health.107  Historically reproductive health has been defined from the
standpoint of white American women’s struggle for access to contracep-
tion and abortion.108  A reproductive justice analysis widens the conversa-
tion and focuses on all-encompassing long-term ends: better lives for
women, healthier families and sustainable communities.  Reproductive
justice will be achieved only when women and girls have the economic,
social and political power and resources to make healthy decisions about
their bodies, sexuality and reproduction for themselves, their families and
their communities in all areas of their lives.  I will examine how fertility
preservation for medical reasons ties into the goal of reproductive justice.
In this Part, I attempt to create a framework to analyze fertility preser-
vation for medical reasons through a reproductive justice lens.  To that
end, first I focus on the health aspects of this technology.  Next, I focus on
fertility preservation for medical reasons through a reproductive rights
perspective.  Finally, I analyze this technology through a fairness perspec-
tive.  Through this framework, I unpack how increasing access to fertility
preservation for medical reasons, as well as increasing access to health
care in general, helps poor and minority women overcome class and
power disadvantages to achieve reproductive justice.
105. See Zakiya Luna, From Rights to Justice: Women of Color Changing the Face of US Repro-
ductive Rights Organizing, 4 SOCIETIES WITHOUT BORDERS 343, 350–51 (2009).
106. See id. at 358.
107. See id.
108. See Sarah London, Reproductive Justice: Developing a Lawyering Model, 13 BERKELEY J.
AFR.-AM. L. & POL’Y 71, 82 (2001).
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Fertility Preservation for Medical Reasons and Health
The reproductive health component of a reproductive justice model
traditionally focuses on women’s access to reproductive health services.109
It emphasizes the importance of women’s access to, and understandings
of, medical services such as pap smears, pre- and post-natal care, abortion
services and counseling, family planning, access to safe and effective con-
traception, and other sexually transmitted infections.110  It closes health
disparities through the creation of clinics, educational outreach, and
agencies designed to provide women with a full range of affordable, cul-
turally sensitive, health services. But true reproductive justice should look
at the whole health of a woman, and not just the reproductive potential.
In this section, I consider the whole health of the individual, not just re-
productive health.
When examining fertility preservation for medical reasons, the dispar-
ities in medical outcomes for minorities must be acknowledged.  African
Americans are behind in terms of life expectancy and infant mortality
compared with other populations.111 Generally, ethnic minorities have
less access to healthcare and have a poorer health status overall.112  Also,
African Americans face a greater risk from dying of a whole host of dis-
eases, including stroke, certain cancers, and diabetes.113  The Centers for
Disease Control and Prevention report that cancer death rates for women
are highest among African Americans, followed by Caucasians, Hispan-
ics, and Asian/Pacific Islanders. Cancer has been the leading cause of
death for female Asian Americans since 1980.114
Race affects the quality of health care minority patients are given.115
Unfortunately, there is proven racial bias in the practice of health care.116
The source of this “pervasive, often subtle discrimination,” is often diffi-
cult to determine.117  Some of the discrimination is caused by providers
who discriminate against certain races and also the lack of access to prov-
109. See id. at 76.
110. See id. at 97.
111. See Kenneth D. Kochanek et al., Deaths: Final Data for 2009, NAT’L VITAL STATS. REPS.,
Dec. 29, 2011, at 1, 3 (Table A noting that in 2008 and 2009, the life expectancy for
whites was higher than for African Americans, and that the infant mortality rates
for African American infants was double the infant mortality rates for whites dur-
ing the same period).
112. See Lisa A. Cooper & Debra L. Roter, Patient-Provider Communication: The Effect of
Race and Ethnicity on Process and Outcomes of Healthcare, in UNEQUAL TREATMENT:
CONFRONTING RACIAL AND ETHNIC DISPARITIES IN HEALTH CARE 552, 570 (Brian D.
Smedley et al. eds., 2003).
113. Office of Minority Health, Health Disparities Experienced by Black or African Ameri-
cans—-United States, CDC (Jan. 14, 2005), reprinted in 293 JAMA 922 (2005).
114. See id.
115. See Barbara Noah, The Role of Race in End-of-Life Care, 15 J. HEALTH CARE L. & POL’Y
349, 351 (2012). See also CARA JAMES ET AL., HENRY J. KAISER FAMILY FOUND., KEY
FACTS: RACE, ETHNICITY, & MEDICAL CARE 7–12 (2007), available at http://www.kff
.org/minorityhealth/upload/6069-02.pdf (documenting the prevalence of health
disparities by condition, insurance status, and utilization of primary and preventive
care and specialist care).
116. See JAMES ET AL., supra note 112.
117. M. Gregg Bloche, Race and Discretion in American Medicine, 1 YALE J. HEALTH POL’Y
L. & ETHICS 95, 98 (2001).
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iders in African American communities.118  Additionally, African Ameri-
cans have higher rates of hospitalization and death in part structural
racial bias.119
Also, class has an effect on cancer survival.  Cancer has a dispropor-
tionately severe impact on the poor.  More often than not, minorities are
likely to be poor.  A Pew Research Center study noted that “[t]he median
wealth of white households is 20 times that of black households and 18
times that of Hispanic households,”120 the largest gap since the govern-
ment began publishing this information.121 Some of the disproportionate
impact has been attributed to delayed diagnosis as well as poor patient
care.  Poor people who lack health insurance or have inadequate access to
quality cancer treatment also experience higher cancer incidence, higher
mortality rates, and lower survival rates than their more well off
counterparts.122
When focusing specifically on reproductive health and fertility preser-
vation for medical reasons, the obvious issue is infertility.  Infertility is a
problem that affects all races, but Blacks have lower fertility rates than
other races after the age of twenty-five.123 Nevertheless, women of color
are significantly less likely to seek aid to help their infertility.124  Below
under the reproductive rights discussion, I delve into the effects of this
lack of access.
Fertility Preservation for Medical Reasons and Reproductive Rights
The reproductive rights component in this reproductive justice analy-
sis is a legal-advocacy based model designed to protect women’s access to
reproductive health care at the state and federal levels.125  Black women
have much lower rates of use of ART than other races.126  This appears to
the based on lack of insurance coverage and lack of access. Fertility clinics
seem to recognize this.  One study on fertility clinics’ websites noted that
118. Vernellia R. Randall, Slavery, Segregation, and Racism: Trusting the Health Care System
Ain’t Always Easy! An African American Perspective on Bioethics, 15 ST. LOUIS U. PUB.
L. REV. 191, 210–12 (1996).
119. See Ruqaiijah Yearby, Racial Inequities in Mortality and Access to Health Care, 32 J.
LEGAL MED. 77, 90 (2011). See also Council on Ethical & Judicial Affairs, Am. Med.
Ass’n, Black-White Disparities in Health Care, 263 JAMA 2344, 2344 (1990) (stating that
though African Americans need to access health care more than others, they have
less of a chance of obtaining the required services).
120. See Noah, supra note 112, at 350.
121. See Yearby, supra note 119.
122. See id.
123. June Carbone, If I Say “Yes” to Regulation Today, Will You Still Respect Me in the Morn-
ing?, 76 GEO. WASH. L. R. 1747, 1749 (2008).
124. Janelle Richards, Cost and Culture Keeping Black Women out of Infertility Centers, THE
GRIO (Mar. 10, 2011, 8:16 AM), http://www.thegrio.com/health/cost-and-culture-
keeping-Black-women-out-of-infertility-centers.php.
125. This component protects woman’s reproductive rights by protecting her right to
privacy, her right to make choices, her right to be free from discrimination, her right
to access services and her actual access to social resources. Discussions of reproduc-
tive rights in the U.S focus primarily on keeping abortion legal and increasing ac-
cess to family planning services.
126. See Noah, supra note 115.
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62.93% of fertility clinic websites examined had pictures of only white
babies.127  Critics of ART have deemed the “technology largely reserved
for the wealthy and the White,” even though a disproportionate number
of infertile women in this country are Black.128 Scholar David Orentlicher
has noted that when health insurance does not cover infertility treatments
and couples (or individuals) must pay out of pocket, then “the significant
costs of these treatments mean that they tend to be reserved for wealthier,
white couples who can pay for them out of personal resources.”129  In-
creased rates of infertility and less access to ART means that minority
populations have to live with the consequences of infertility while others
do not.130
The Affordable Care Act (ACA) increases the number of people who
will have access to health insurance, so this could help even the playing
field in terms of health outcomes for minority cancer patients.  However,
the ACA does not require states to cover IVF, fertility preservation, or
other forms of ART.  To protect the reproductive rights of poor and mi-
nority cancer patients, it may be necessary to require such insurance cov-
erage.  This lack of ART coverage seems to be based upon insurance
status and cost.131  For reproductive fairness, insurers and the federal gov-
ernment are in a better position to bear the cost burden of ART services
rather than poor or minority cancer patients.  In past cases, when the cost
barrier to care was substantially lessened or eliminated, such as when
Blacks joined the military and enjoyed healthcare coverage for ART, utili-
zation of fertility treatment by African Americans became proportional
and underutilization less of a problem.132
Property Rights in Fertility Preservation for Medical Reasons
There are numerous other legal issues affecting reproductive rights
that must be addressed if fertility preservation becomes more common.
Just as in other areas of ART, there will be disputes over the ownership,
use, and disposal of tissues, eggs, sperm, and embryos.  In most ART,
there are concerns about how stored bodily material (gametes, embryos,
gonads, gonadal tissue) will be used and disposed of.133  However, in fer-
127. See Jim Hawkins, Selling ART: An Empirical Assessment Of Advertising On Fertility
Clinics’ Websites, 88 IND. L.J. 1147, 1169 (2013).
128. See Kimberly M. Mutcherson, Transformative Reproduction, 16 J. GENDER RACE & JUST.
187, 222 (2013).
129. Orentlicher, supra note 50, at 181.
130. See Marcia C. Inhorn & Michael Hassan Fakih, Arab Americans, African Americans,
and Infertility: Barriers to Reproduction and Medical Care, 85 FERTILITY & STERILITY 844,
845 (2006). See also Eve C. Feinberg et al., Comparison of Assisted Reproductive Technol-
ogy Utilization and Outcomes Between Caucasian and African American Patients in an
Equal-Access-to-Care Setting, 85 FERTILITY & STERILITY 888, 890 (2006); Maurizio Maca-
luso et al., A Public Health Focus on Infertility Prevention, Detection, and Management,
93 FERTILITY & STERILITY 16.e1, 16.e2 (2010).
131. See Feinberg et al., supra note 124, at 889.
132. See id at 893.
133. See Sarah Rodriguez et al., Fertile Future? Potential Social Implications of Oncofertility,
31 J. OF CLINICAL ONCOLOGY 665, 665–67 (2013).  It has been noted that future use
and disposal of gonads and gonadal tissue are different than use and disposal of
embryos and gametes, depending upon whether gonads and gonadal tissue is clas-
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tility preservation for medical reasons, the primary purpose of extracting
these materials is to store them for the future, especially in the case of
children with such diseases who may not use their preserved materials
for several years.134  Also, because those involved are cancer patients, they
have an increased likelihood of death than other ART patients.135  So is-
sues of disposition and ownership are even more important in this popu-
lation because they are sick and more likely to die than others who are
using ART.136  Cases regarding property rights in frozen embryos are
commonplace in ART, and they are becoming more common in oncofer-
tility cases.137
sified as organs or as gametes. See id.  There needs to be additional thought to what
type of classification makes the most sense to avoid court disputes and moral dilem-
mas. See id.  If such materials are classified as organs, they may be subject to alloca-
tion rules under the United Network of Organ Sharing.  See id.
134. See id at 665.
135. See id.
136. See id.
137. In another disposition case, Szaafranski v. Dunston, the Circuit Court of Cook
County, Illinois originally granted Dunston (the ex-girlfriend) summary judgment
and full custody of pre-embryos she created with Szafranski (the ex-boyfriend).
Szaafranski v. Dunston, 993 N.E.2d 502, 503 (Ill. App. Ct. 2013).  Szafranski ap-
pealed, claiming that summary judgment was inappropriate as there were still is-
sues of fact to resolve, and that his consent was required to use those pre-embryos
under the privacy and liberty rights of both the United States and Illinois Constitu-
tions.  See id. The embryos were created when Dunston asked Szafranski to donate
his sperm in order to create embryos following her diagnoses of non-Hodgkin’s
lymphoma and subsequent chemo treatments.  See id.  When the couple met with
doctors to deposit the sperm, they signed an informed consent form that stated,
“[n]o use can be made of these embryos without the consent of both partners (if
applicable),” as well as a disclaimer regarding the unsettled state of the law regard-
ing in vitro fertilization.  Id. at 504.  After meeting with an attorney, a co-parent
agreement was drafted, but never signed.  See id..  It indicated that they would both
be legal co-parents of any children that resulted from their embryos.  See id.  This
agreement specifically stated that Szafranski “agrees to undertake all legal, custo-
dial, and other obligations to the Child regardless of any change of circumstance
between the Parties,” and that “[s]hould the Intended Parents separate, Karla will
control the disposition of the pre-embryos.”  Id.  Shortly after three viable embryos
were created, the couple ended their relationship, and Szafranski filed a complaint
in circuit court to enjoin Dunston from using the pre-embryos.  See id. at 504–05.
The Circuit Court granted Dunston’s motion for summary judgment and denied
Szafranski’s motion for summary judgment, giving Dunston “full custody and con-
trol over the disputed pre-embryos . . . and [stating that she] may use them to at-
tempt to have children.”  Id. at 506.  Szafranski appealed, and the Court considered
the issue of first impression of “who controls the disposition of cryopreserved pre-
embryos created with one party’s sperm and another party’s ova.”  Id.  The Court
noted that there are three ways to approach this issue: (1) a contractual approach,
(2) a contemporaneous mutual consent approach, and/or (3) a balancing approach.
See id.  Each party argued for a different approach, and the Court ultimately chose
to honor the mutually expressed intent of the parties, as set forth in prior agree-
ments (the contract approach), reasoning that this “properly allows them, rather
than the courts, to make their own reproductive choices while also providing a
measure of certainty necessary to proper family planning.”  Id. at 515. The Court
also believed that this will encourage couples to seriously discuss their “desires,
intentions, and concerns” with each other before participating in in vitro fertiliza-
tion.  Id.  The Court further held that “where there has been no advance agreement
regarding the disposition of pre-embryos, ‘then the relative interests of the parties
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To protect the cancer patient, there should be a clear agreement of
who owns the biological material and what will happen to it should the
patient die.  One can imagine a truth-is-stranger-than-fiction scenario
where a grieving mother may wish to use a surrogate, or worse implant
in her own womb, her child’s preserved eggs in order to have a posthu-
mously conceived grandchild.  With greater access to technology comes
the reality that the unreal can and may happen.  One must ensure that the
parent is making the decision to preserve a child’s reproductive potential
with the best interests of the child in mind, not as a back-up grandchild.
It is difficult to draw hard and fast rules but allowing for the tissue or
eggs to be donated or destroyed in the case of the patient’s death should
be agreed upon in advance to avoid the crazy stories that ART sometimes
brings.
Garden variety cases that come up any time eggs or embryos are
formed have come up in fertility preservation for medical reasons cases
as well.  Ownership of embryos created for the purpose of fertility preser-
vation should be clearly delineated at the time of the embryo creation to
avoid legal wrangling and unjust results.  For example, in one case, a hus-
band and wife created thirteen pre-embryos after finding out that the
wife had breast cancer.138  The wife underwent two surgeries, eight
rounds of chemo, and thirty-seven rounds of radiation, making her una-
ble to have children.139  The couple divorced and the divorce court
awarded the pre-embryos to the wife, reasoning, “that the pre-embryos
are marital property subject to equitable distribution.”140  The lower court
applied a balancing test, finding that the “Wife’s inability to achieve bio-
logical parenthood without the use of the pre-embryos is an interest
which outweighs [the] Husband’s desire to avoid procreation.”141  While
the couple did sign an informed consent form for storage of the pre-em-
bryos stating that storage was not to exceed three years, the Court inter-
prets this as an agreement between the couple and the storage company,
not an agreement between the husband and wife to destroy the pre-em-
bryos at that point.142
in using or not using the preembryos must be weighed.’”  Id..  The Court found no
basis for Szafranski’s constitutional arguments and dismissed them.  See id. at
516–17.  The Court then remanded the matter to the Circuit Court with an order to
apply the contract approach to the facts/evidence at hand.  See id. at 517–18.
138. See Reber v. Reiss, 42 A.3d 1131, 1132–33 (Pa. Super. Ct. 2012).
139. See id at 1133.
140. Id.
141. Id. at 1134. (quoting the lower court’s opinion).  The Superior Court of Pennsylvania
reviewed the husband’s appeal for abuse of discretion, ultimately affirming the
lower court’s order. See id.  The Court notes there are three approaches (contract,
contemporaneous mutual consent, and balancing) to resolving the issue of first im-
pression surrounding “the contested disposition of frozen pre-embryos in the event
of divorce.” Id.  The Court reasoned that it does not need to adopt one approach
over another, because the lower courts applied the balancing test in the absence of a
signed provision related to the pre-embryos in the event of divorce, and the hus-
band and wife could not come to a contemporaneous mutual agreement. See id. at
1136.
142. See id. at 1336.
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The Superior Court then considered whether the lower court properly
applied the balancing standard.  The Court ultimately agreed with the
lower court that, “because [the] Wife cannot achieve genetic parenthood
otherwise . . . [the] Wife’s interest in biological procreation through the
use of these pre-embryos outweighs [the] Husband’s professed interest
against procreation.”143  While the husband argued that the wife could
become a mother through different means (adoption or being a foster par-
ent), in relation to balancing the wife’s interest, the Court stated that,
There is no question that the ability to have a biological child and/
or be pregnant is a distinct experience from adoption. Thus, sim-
ply because adoption or foster parenting may be available to [the]
Wife, it does not mean that such options should be given equal
weight in a balancing test. Adoption is a laudable, wonderful, and
fulfilling experience for those wishing to experience parenthood,
but there is no question that it occupies a different place for a wo-
man than the opportunity to be pregnant and/or have a biological
child.144
The Court ultimately found that the wife had a compelling interest in
using the pre-embryos to have a baby because they are “likely her only
chance at genetic parenthood and her most reasonable chance for
parenthood at all.”145  The Court found that this interest superseded the
husband’s interest in this case.146  The Court also rejected the husband’s
argument that he only agreed to create the pre-embryos as a “safeguard,”
and that he never actually planned on having a baby with the wife.147  The
Court stated that the only reason someone would undergo in vitro fertili-
zation is to have a child, and that his participation in the process shows
that he clearly understood that a potential child would result from it.148
The Court finally dismissed the husband’s argument that “it is against
Pennsylvania public policy to force him to procreate with [his] Wife when
he does not want to do so,” as never being addressed by the Penn-
sylvania courts.149  The Court ultimately agreed with the trial court that in
balancing all of these factors, the scale tips in the wife’s favor.150  Even in
the reasoning of this case, which relates to the ownership of the embryos,
one sees the preference given towards the ability to have a biologically
related child.
Fertility Preservation for Medical Reasons and Reproductive Fairness
In this section, I explore how reproductive fairness can be achieved for
patients facing infertility due to medical reasons.  In this section, I attempt
to theorize how to organize individuals and communities to create struc-
tural change and challenge power inequalities that this population is fac-
143. Id. at 1137 (quoting the lower court’s opinion).
144. Id. at 1138–39.
145. Id. at 1140.
146. See id.
147. Id.
148. See id.
149. Id. at 1142.
150. See id.
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ing. “Reproductive fairness” includes social justice for entire
communities, and requires a complete vision of health for women and
girls including an understanding of issues such as sex trafficking, youth
empowerment, women’s health, family well-being, educational justice,
unsafe working conditions, domestic violence, immigration injustices, en-
vironmental racism, and globalization.151  This section is intended to be a
starting point for the generation of “new patterns of thinking” and to
offer a “fresh approach to creating unifying and intersectional lan-
guage”152 with which to build bridges across racial and class fissures that
prevent productive conversations on race, rights and reproduction.
Gaining Trust
One important issue to consider when trying to empower vulnerable
cancer patients with information and potential access to fertility preserva-
tion services is trust.  Trust is gained by true and detailed informed con-
sent—which includes discussions of a physician’s competing loyalties (for
example, if he or she is being paid to be part of an experimental protocol.)
Many minorities and immigrants may distrust the medical system and
experimental therapies due to the United States’ haunting history of treat-
ing minorities as guinea pigs without their consent.153  Slaves in the
United States were often used in medical experimentation without
knowledge or consent.154  One particularly horrifying incident occurred
when one doctor performed multiple painful surgeries without using an-
esthesia on slave women who suffered from vesico-vaginal fistula.155 The
Tuskegee syphilis experiment has gained notoriety because the United
States Public Health Services experimented on 400 poor Black men with
syphilis for over forty years in which they were never told they had the
disease and denied proper medical treatment, even when it was readily
available.156  Less well known are two studies, one occurring in 1963 in
which doctors injected live cancer cells into twenty-two chronically ill,
poor African American women without their consent or knowledge, and
another study of twenty women who were primarily poor, young and
Black on an experimental medical device used to induce abortions despite
general consensus in the medical community that this device should not
be used.157  Such a history has often caused African Americans to distrust
medical research and the medical community in general.  But members of
several groups share this history.  For example, a medical experiment on
Latino boys on psychiatric drugs has contributed to decreased trust in the
151. Loretta Ross, Understanding Reproductive Justice: Transforming the Pro-Choice
Movement, 56 (4) Off Our Backs 14, 14 (2007)
152. See id.
153. Randall, supra note 115, at 191 (noting that many African Americans fear and dis-
trust the health care system as a result of historical abuses, which reflects their
views of the system).
154. See TODD L. SAVITT, MEDICINE AND SLAVERY: THE DISEASES AND HEALTH CARE OF
BLACKS IN ANTEBELLUM VIRGINIA 293 (1978).
155. See id.
156. See JAMES H. JONES, BAD BLOOD: THE TUSKEGEE SYPHILIS EXPERIMENT 5–9 (1993).
157. Alvis V. Adair, Human Experiment: An Ancient Notion in a Modern Technology, INST.
FOR URBAN AFFAIRS AND RESEARCH, HOWARD UNIV., 1974, at 1, 9–10.
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Latino community in the medical profession.158  Asians have similarly suf-
fered worse health outcomes due to discriminatory practices in health
care delivery.159  The poor and immigrants have been experimented upon
many times.160 This history contributes to distrust of doctors by members
of minority communities.161  Because many of the fertility preservation
techniques are indeed experimental, there must be an effort to ensure that
the poor and uneducated and minority patients are protected.
Another point to consider when examining fertility preservation for
medical reasons through a reproductive justice framework is to consider
the history of sterilization of Black women, often with the assistance of
public funding or in public hospitals.162 Black’s Law Dictionary defines
“sterilization” as “[t]he act of making (a person or other living thing)
permanently unable to reproduce.”163  Not informing Black women of
their reproductive options while undergoing cancer therapy can be seen
as a “softer” form of sterilization, especially if Black women are not in-
formed of their fertility preservation options as often as other races.  The
lack of trust that the history of sterilizations brings must be addressed,
and giving patients detailed, consistent information may help garner
more trust.
This history has resulted in a skepticism and distrust of medical care
and medical interventions by the Black community.  Physicians must be
sensitive to this potential and spend time with Black patients explaining
fertility preservation.  The studies cited earlier show that physicians are
often not even addressing fertility preservation with minority patients.
This is a problem because it could be seen as the medical community
further limiting reproductive rights of Blacks.  This must be balanced
158. See Marianne Engelman Lado, Unfinished Agenda: The Need for Civil Rights Litigation
to Address Race Discrimination and Inequalities in Health Care Delivery, 6 TEX. F. ON
C.L. & C.R. 1, 11 (2001).
159. See generally ANNE FADIMAN, THE SPIRIT CATCHES YOU AND YOU FALL DOWN: A
HMONG CHILD, HER AMERICAN DOCTORS, AND THE COLLISION OF TWO CULTURES
(1997); see also Rose Cuison Villazor, Community Lawyering: An Approach to Address-
ing Inequalities in Access to Health Care for Poor, of Color and Immigrant Communities, 8
N.Y.U. J. LEGIS. & PUB. POL’Y 35, 39 (2005) (describing discrimination in healthcare,
medical care and medical facilities based on race, ethnicity and language).
160. See DIANA SCULLY, MEN WHO CONTROL WOMEN’S HEALTH: THE MISEDUCATION OF
OBSTETRICIAN-GYNECOLOGISTS 45 (1980) (describing how a New York Women’s Hos-
pital engaged in surgical experimentation on impoverished immigrant women new
to New York City in the mid-1800s); see generally DEBORAH KUHN MCGREGOR, SEX-
UAL SURGERY AND THE ORIGIN OF GYNECOLOGY: J. MARION SIMS, HIS HOSPITAL, AND
HIS PATIENTS (1989) (describing how doctors performed medical experiments on
poor women).
161. See Irena Stepanikova et al., Patients’ Race, Ethnicity, Language, and Trust in a Physi-
cian, 47 J. HEALTH & SOCIAL BEHAV. 390, 401 (2006) (noting that minority patients’
knowledge of a history of discrimination in healthcare may decrease their confi-
dence in doctors); see also William D. King, Comment, Examining African Americans’
Mistrust of the Health Care System: Expanding the Research Question, 118 PUB. HEALTH
REPS. 366, 366 (2003); see also Giselle Corbie-Smith, Distrust, Race, and Research, 162
ARCHIVES INTERNAL MED. 2458, 2459–60 (2002) (concluding that African Americans
were significantly more likely than whites to believe that their doctors would not
fully disclose the risks of research participation).
162. See ANGELA Y. DAVIS, WOMEN, RACE AND CLASS 215–21, 216 (1981).
163. Black’s Law Dictionary 717 (4th ed. 2006).
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with the fact that these technologies are in their infancy, and there is a
fear of experimentation within this community.  Physicians must be
forthright in the fact that fertility preservation does contain physical risks
and is not a guarantee, and also open a dialogue with a minority patient
about the process of preservation and the potential of IVF in the future.
An additional part of the problem has been that minorities are diagnosed
with cancer at a later stage, and there is less time to consider fertility
preservation.  Better health care and health equity for all will help allevi-
ate this disparity and ensure doctors also have enough time to consider
fertility preservation for this population.  Some have suggested that given
the fast pace change in the science of fertility preservation, a specialized
team, rather than just an oncologist, may be needed to provide fertility
preservation information.164
Increasing Health Literacy
In addition to trust, in order to have true reproductive justice in fertil-
ity preservation for medical reasons, the health literacy of all populations
must be enhanced through education and detailed, simplified informed
consent.165  Health literacy means the ability to obtain, understand, and
utilize health information to make sound health decisions.166  Thus, in-
formed consent forms that are written in language above the average pa-
tient’s reading level fail the health literacy standard.167  Someone must
discuss the informed consent standards related to fertility preservation
for medical reasons and not just hand a vulnerable patient a form. Also,
language barriers and technological barriers may be a problem for those
encountering the health care system.168  Thus, for those who may have
difficulty understanding English, translation of materials and conversa-
tions is important for true health literacy.
The Goal of Biological Parenthood
Another reproductive justice issue to consider with fertility preserva-
tion for medical reasons is whether it reinforces the ultimate goal of bio-
164. Jennifer Levine et al., Fertility Preservation in Adolescents and Young Adults with Can-
cer, 28 J. CLINICAL ONCOLOGY 4831, 4831 (2010).
165. Brietta Clark, Using Law to Fight a Silent Epidemic: The Role of Health Literacy in Health
Care Access, Quality, and Cost, 20 ANNALS HEALTH L. 253, 257–58, 284 (2011).
166. See id. at 258.
167. See Ad Hoc Comm. on Health Literacy for the Council on Scientific Affairs, Am.
Med. Ass’n, Health Literacy: Report of the Council on Scientific Affairs, 281 JAMA 552,
553–54 (1999).
168. See Mark V. Williams et al., Inadequate Functional Health Literacy Among Patients at
Two Public Hospitals, 274 JAMA 1677, 1679–80 (1995) (noting that approximately 30
percent of English-speaking patients in one study location could not understand
simple written health instructions); see, e.g., HENRY J. KAISER FAMILY FOUND., THE
DIGITAL DIVIDE AND ACCESS TO HEALTH INFORMATION ONLINE, (2011), available at
http://www.kff.org/kaiserpolls/upload/8176.pdf (noting that, although the gap is
somewhat closing, racial and ethnic disparities in computer and Internet access re-
main substantial and that these disparities foreclose opportunities to access health
information online).
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logical parenthood.169 Dorothy Roberts has written on fertility
preservation for medical reasons and has noted that technological solu-
tions to social problems often result in further oppressing already-disad-
vantaged groups.170  Roberts notes that there is a fine line between
informed consent—where patients are informed by oncologists about fer-
tility preservation—to a sort of coercion, where parents of minor patients
and adult female patients feel pressured into freezing their eggs because
of the chance at biological motherhood.171  Roberts questions the narrative
that fertility preservation improves the reproductive rights of all women.
In fact, the physical risks of the fertility preservation egg retrieval or tis-
sue retrieval and the potential delay in cancer therapy should be assessed
critically.  Because Black women are often treated later in their cancer
progression, any delay may negatively impact their survival chances.
Also parents of cancer patients should not be made to feel like they are
somehow sterilizing their child by choosing not to preserve their child’s
reproductive tissue.  There needs to be an informed consent discussion
that takes the time to consider all the options.  While the AMA and OSCO
policies suggesting the discussion of fertility preservation are laudable in
increasing options for patients, the standard of care should include a full
discussion of reproductive options after cancer treatment.  As mentioned
earlier, studies have shown that some women regain their reproductive
potential naturally after cancer treatment.172
Adoption is another option that should be included in a discussion of
reproductive justice.  Just because it is theoretically possible to preserve a
woman’s fertility, it is not a sure thing.  In fact, except for egg or sperm
freezing, which can only occur in post pubescent patients and has re-
sulted in live births, the other fertility preservation techniques have re-
sulted in less than a handful of live births.  Relying on the marvels of
fertility preservation alone during post cancer treatment may not be a
wise choice.  The medical community should be trained to discuss alter-
natives to biological parenthood, such as adopting a child.  To be sure, not
every woman must be a mother at all, but given the history of limiting
minority mothering rights, I err on the side of aiding in all forms of moth-
erhood, rather than acknowledging that one can have a happy fulfilled
life without being a parent.  The “medical miracle” of fertility preserva-
tion for medical reasons should not mean that improving access to other
avenues of parenthood should be abandoned.  Adoption is a long, expen-
sive, and exclusive process in the United States, and even more so for
cancer survivors.173  Adoption is often only an option to healthy, married
169. See Shauna L. Gardino & Linda L. Emanuel, Choosing Life When Facing Death: Under-
standing Fertility Preservation Decision-Making for Cancer Patients, in ONCOFERTILITY:
ETHICAL, LEGAL, SOCIAL, AND MEDICAL PERSPECTIVES 447, 447 (Teresa K. Woodruff et
al. eds., 2010).
170. See Dorothy E. Roberts, The Social Context of Oncofertility, 61 DEPAUL L. REV. 777, 797
(2012).
171. See id. at 783.
172. See Green, supra note 37.
173. Shauna L. Gardino et al., Adoption After Cancer: Adoption Agency Attitudes and Per-
spectives on the Potential to Parent Post-Cancer, CANCER TREAT RES., 2010, at 153, availa-
ble at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086473/.
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young couples.174 Some adoption agencies indicate that the number of
disease-free years is a relevant consideration while others are simply una-
ware of the importance of the information.175  Just because fertility preser-
vation technology exists and could be made use of may actually worsen
the bias against adoption by those with cancer in their pasts.  As one
scholar suggests, fertility preservation for medical reasons should really
be regarded not as “preserving the possibility of motherhood” but rather
“increasing the number of paths to motherhood from which a woman
might later choose.”176  Dorothy Roberts notes that several psychological
studies show that infertile people who adopt children have levels of well
being similar to those who succeed with fertility treatments.177  However,
is it just to deny these procedures to poor and minority women when
affluent women who can afford it have access to them?  Just because stud-
ies show that women are happy adopting, should the medical community
and society just pat poor and minority women on the back and say,
“Don’t worry, you can always adopt”?  It does not seem fair to deny bio-
logical motherhood on the basis of wealth.  Roberts’s criticisms should be
taken into account, but there are ways to allow women access to have a
biological child, without making biological motherhood a normative
ideal.  More options, rather than less, seems to be a better road to repro-
ductive justice.  One of the ways to do is to move towards a model of
informed consent that does not make value judgments of biological moth-
erhood as being preferential to another type of parenthood or perhaps not
becoming a parent.
Informed Consent Under a Reproductive Justice Model
Art Caplan, a noted bioethicist, has argued that as long as the stan-
dards of informed consent are met, offering fertility preservation services
to cancer patients may be appropriate even though these involve experi-
mental treatments.178  Given the history of experimentation and justifiable
distrust of the medical and research communities by members of minor-
ity communities, this section attempts to define what appropriate in-
formed consent for fertility preservation for medical reasons would look
like in a reproductive justice model.  Our modern notions of informed
consent stem from the classic 1972 case Canterbury v. Spence,179 which
adopted a patient centered model of informed consent.  Because studies
have shown that African American cancer patients are not informed of
174. See id.
175. See id.
176. Christina L. H. Traina, Ovarian Tissue Cryopreservation and Bioethical Discourse, in
ONCOFERTILITY: ETHICAL, LEGAL, SOCIAL, AND MEDICAL PERSPECTIVES 171, 173, 177
(Teresa K. Woodruff et al. eds., 2010).
177. See Roberts, supra note 165, at 790 (citing Carolyn McLeod, Morally Justifying
Oncofertility Research, in ONCOFERTILITY: ETHICAL, LEGAL, SOCIAL, AND MEDICAL PER-
SPECTIVES 187, 191).
178. See Pasquale Patrizio & Arthur L. Caplan, Ethical Issues Surrounding Fertility Preser-
vation in Cancer Patients, 53 CLINICAL OBSTETRICS & GYNECOLOGY 717, 718 (2010).
179. 464 F.2d 772, 780 (D.C. Cir. 1972) (“Every human being of adult years and sound
mind has a right to determine what shall be done with his own body . . . .”) (quot-
ing Schloendorff v. Soc’y of N.Y. Hosp., 105 N.E. 92, 93 (N.Y. 1914)).
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fertility consequences of cancer treatment compared with other pa-
tients,180 it is important to ensure that the standard of care is to inform all
patients of the risks to fertility of cancer treatment itself.  Just because a
patient already has children or is under- or uninsured should not affect
the information that the patient receives about fertility preservation op-
tions and availability.  Patients should receive information about the risks
of the options to the patients and potential risks to the offspring con-
ceived through ART.  They should also receive information about the cost
of this option and whether their insurance will cover it.  Additionally, a
physician should fully disclose any financial interests or conflicts of inter-
est that he or she may have.  These could include being an investigator as
part of an experimental fertility preservation study or protocol or having
a financial interest in any cryopreservation business or storage facility.
One can see how this conflict of interest may affect how positive an as-
sessment a physician gives fertility preservation.  Additionally, because
of the disparities in cancer treatment success rates and survival rates be-
tween races, a physician must realistically disclose the impact of fertility
preservation on the cancer treatment regimen itself.  Also, because this is
a new field, physicians should not give false hope to patients who already
are vulnerable due to their diagnosis.  They should give realistic statistics
about the potential success of fertility preservation options.  At the same
time, they should present information about adoption as an option but
also inform patients about the roadblocks they may face adopting as a
cancer survivor.  The ASCO policy of informing patients about fertility
preservation should be amended to acknowledge racial and demographic
disparities that exist in informing patients about fertility preservation and
recommend that physicians disclose this option to all patients, regardless
of race and prognosis.  To be sure, someone with a Stage IV cancer diag-
nosis may be more worried about his or her own survival than fertility
preservation, but that should be a decision for that patient to make.  The
process of informed consent and fertility preservation discussion edu-
cates patients and helps them be more empowered navigating through
the medical system.  Especially in minority populations, where people
may not feel as comfortable within the medical system, a robust discus-
sion involving the patient’s options may go a long way in gaining some
trust in the system, regardless of whether one chooses to undergo fertility
preservation.  If such a discussion results in more minorities seeking fer-
tility preservation or at least feeling more in control of their health and
future, this would be a step towards regaining trust in the medical
system.
Informed consent is also complicated when a parent is consenting for
a mature child or adolescent.  Especially in the case of adolescents, they
should be made part of the informational process related to fertility pres-
ervation and their feelings on the subject should be taken into account.
180. See Shnorhavorian, supra note 54.
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Reproductive Justice and Lack of Health Insurance Coverage
Whenever fertility preservation for medical reasons is discussed, the
high costs of the procedures used to preserve fertility must be acknowl-
edged.181 Who should pay for the preservation of these materials?  The
AMA policy and the California bill advocate for insurance companies to
cover fertility preservation for medical reasons services. Some scholars
argue that even if insurance companies do not cover other forms of ART,
they should cover fertility preservation for medical reasons services be-
cause it does not differ from other treatments for iatrogenic conditions
currently covered for patients with cancer.  Under a reproductive justice
framework, it is important to consider whether this is the wisest use of
health care resources given that only 10% of cancers affect those younger
than 45.182  Also, the success rates of fertility preservation efforts are mod-
est at best right now.  True, they may get better if there were more partici-
pation—which insurance coverage may guarantee—but perhaps the
money would be better spent helping poor and minority communities
gain better access to health care.  Without insurance coverage, those who
are able to pay for fertility preservation for medical reasons will likely be
the same population that accesses ART: white, educated, middle- and up-
per class.183  However, some note that the lack of insurance coverage for
fertility techniques has profoundly limited access to care for underserved
populations.  If the ability to have a biological child is a right,184 arguably
these technologies should be made available to all individuals experienc-
ing infertility, including those patients facing fertility-threatening thera-
pies.185  At the heart of class issues in fertility preservation for medical
reasons lies the fact that fertility preservation, and specifically the har-
vesting and storage of eggs, is expensive.186  Low-income women and
those facing poverty are often unable to use any of these services,187 and
the factors bearing directly on that class of women include race, educa-
tion level, and marital status.188  The question then becomes whether sub-
181. See JAMES et al., supra note 112, at 7–12 (noting that insurance status and socioeco-
nomic status contribute to poorer overall health status for racial and ethnic minority
groups).
182. See Basco et. al., supra note 89, at 835.
183. See Rodriguez et al., supra note 127, at  666; see also Tarun Jain, Socioeconomic and
Racial Disparities Among Infertility Patients Seeking Care, 85 FERTILITY AND STERILITY
876, 879–80 (2006) (noting that even in states with mandated infertility coverage,
significant racial disparities exist with regards to seeking infertility care) .
184. See John A. Robertson, Procreative Liberty and Harm to Offspring in Assisted Reproduc-
tion, 30 AM. J.L. & MED. 7, 19 (2004) (noting that the right to have children is a
widely accepted personal liberty).
185. See Rodriguez et al., supra note 127, at 666 (noting arguments that “insurance com-
panies should cover oncofertility (even if they do not cover other forms of ART),
because it does not differ from other treatments for iatrogenic conditions currently
covered for patients with cancer”).
186. See Roberts, supra note 165, at 790.  Tissue cryopreservation costs average $30,000,
while IVF cycles cost approximately $15,000 and live births from these procedures
cost greater than $40,000. See id.
187. See id.
188. See id. (citing Mary Lyndon Shanley & Adrienne Asch, Involuntary Childlessness, Re-
productive Technology, and Social Justice: The Medical Mark of Social Illness, 34 SIGNS 851,
856 (2009)).
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sidizing fertility preservation will help to reduce the economic disparities
in availability of fertility treatments or whether it will simply privilege
those who are already the most advantaged.189
One argument against such subsidies and the continued funding of
such research and innovation notes that while economic disparities and
barriers are unfortunate, they do not justify interfering with the rights of
those who are already fortunate enough to be able to use such technolo-
gies.190  The argument is that simply because a person has the right to
ART does not obligate the government to provide that ART.191  Although
some may argue that medical innovation may actually increase the class
inequality because only the wealthy will be able to afford such new tech-
nologies, this seems to be flawed reasoning. Innovation need not be sti-
fled and those that can afford access to medical benefits would not be
denied such access.192  Additional coverage does not take away the rights
of those who can afford it outright.  Rather, taking Roberts’s caution into
account, it is possible to have an insurance system that fosters fairness
and closes chasms in reproductive health care.
In fact, fertility preservation should be subsidized, and there should
be equal access to fertility preservation for medical reasons regardless of
wealth.193  Procreation holds special status in a person’s life and has even
been deemed by the United States Supreme Court as “one of the basic
civil rights of man.”194  Thus, the guarantee of equal protection becomes a
compelling reason to ensure access by all to fertility preservation, and the
devaluing of the right of historically disadvantaged groups to procreate
could be seen as a form of state oppression.195
The argument has been made that proposals to mandate insurance
coverage of fertility preservation treatments will only serve to enhance
the disparities, unless programs to ensure equal access to health insur-
ance itself for low-income and poor patients accompany them.196  Millions
of women must rely on Medicaid for medical care, which covers only
those procedures deemed medically necessary.197  Because fertility preser-
vation is considered to be an elective procedure, only those women fortu-
nate enough to have private insurance would have access, leaving the
poorer population in the same position as before mandated insurance
coverage.198
Another argument is that even if subsidies were provided for low-
income women, disparities would still exist in access to types of technol-
ogy available.199  Wealthy women would be able to access newer and bet-
ter technologies and would have the ability to pay for additional services
189. See Roberts, supra note 165, at 791.
190. See id.
191. See id.
192. See id.
193. See id.
194. Id. (quoting Skinner v. Oklahoma, 316 U.S. 535, 541 (1942)).
195. See id.
196. See id.
197. See id. at 791–92.
198. See id. at 792.
199. See id.
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(for example, rather than just one round of IVF, they would be able to
afford multiple rounds if needed).200  In addition, the wealthy may still be
the only ones able to afford certain genetic testing and screening.201  Once
the door is opened for subsidies, the question then becomes how much
the public would be willing to support in order to ensure complete
equality.202
An additional question when considering whether fertility preserva-
tion should be subsidized is whether the resources committed would be
better spent on other areas.203  Some argue that the potential millions of
dollars would benefit a broader range of the population and would be
better spent on research to reduce infertility in general and on the provi-
sion of basic health care.204  However, as fertility preservation for medical
reasons continues to grow and new technologies emerge, it does not seem
realistic to pick general health care over reproductive health.  Rather, ac-
cess to both needs to be increased, and the public will evaluate the prior-
ity given to each.205  The best answer is to advocate for fertility
preservation for medical reasons insurance coverage within a more gen-
eral health care advocacy, which would improve the lives of the unin-
sured, the underinsured, and poor minorities.  Rather than the AMA
policy206 and the California bill that focus only on fertility preservation
alone,207 the policies of the ACA increasing general health care coverage
for more Americans,208 coupled with policies such as these, will help en-
sure that all races get their cancers diagnosed at an earlier stage, which
would help allow more time for fertility preservation dialogue.
V. THE FUTURE OF FERTILITY PRESERVATION FOR MEDICAL REASONS
This Article is meant to start a nuanced discussion about fertility pres-
ervation for medical reasons and whether promoting it fits with our nor-
mative goals as a just, healthy society.  This field is just beginning to take
shape.  There are bound to be more discussions regarding whether to pur-
sue fertility preservation for medical reasons, based on personal convic-
tions and religious beliefs.  In addition, legal issues regarding the
interplay between parents and a child or adolescent patient in determin-
ing the patient’s best interests, and how the child or adolescent whose
ovarian tissue or gametes were stored will feel about using those materi-
als later will definitely need to be explored.
The reproductive justice framework helps to tease out the issues that
still need addressing with fertility preservation for medical reasons.  The
200. See id.
201. See id.
202. See id.
203. See id.
204. See id.
205. See id. at 792–93.
206. See AMA Press Release, supra note 62.
207. See A.B. 912, 2013-2014 Assemb., Reg. Sess. (Cal. 2013).
208. See Janet L. Dolgin & Katherine R. Dieterich, Social and Legal Debate About the Afforda-
ble Care Act, 80 UMKC L. Rev. 45, 52 (2011) (“The Affordable Care Act expands
health care coverage to many people who would not otherwise be protected.”)
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answer does not seem to be to put a stop to this technology—which is
unrealistic and counterproductive.  Detailed discussions about fertility
preservation for medical reasons will help all groups of patients.  There is
evidence that patients with cancer who receive counseling about fertility
preservation experience less long-term regret than those patients who do
not receive counseling, even if the patients choose not to pursue fertility
preservation.209  The answer to promoting reproductive justice should not
be to withhold available information and existing medical technologies
from women, but rather to present all the options to women and make it
easier for them to utilize these options.  To that end, advocating for better
general health care coverage for all Americans and fertility coverage by
private and public insurance is extremely important.  Instead of fearing
that this technology will lead to larger health care disparities, getting all
Americans with a higher base level of coverage will ensure that the gaps
are narrower and that both of these important goals-health care fairness
and reproductive fairness- are achieved.  With greater access to health
care insurance through the ACA, hopefully cancers will be found earlier,
for all races, and with more time to consider fertility preservation as a
viable option.  If insurers begin covering fertility preservation for these
patients, more physicians will likely begin discussing these options to all
patients.  Such a result would go a long way to close the power and class
gap that exists between races and help promote health and reproductive
equality.
209. See Clarisa R. Gracia et al., Lives in the Balance: Women With Cancer and the Right to
Fertility Care, 31 J. OF CLINICAL ONCOLOGY 1, 1 (2013).
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